Literature DB >> 12352407

Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.

Gary K Lefkowitz1, Samir S Taneja, Jordan Brown, Jonathan Melamed, Herbert Lepor.   

Abstract

PURPOSE: Repeat biopsy has been advocated following the diagnosis of high grade prostatic intraepithelial neoplasia to exclude coexisting prostate cancer. We further define the natural history of high grade prostatic intraepithelial neoplasia by determining the incidence of prostate cancer 3 years following diagnosis.
MATERIALS AND METHODS: A total of 31 men underwent followup interval biopsy 3 years after high grade prostatic intraepithelial neoplasia diagnosis in 1996 to 1997, regardless of change in serum prostate specific antigen (PSA) or digital rectal examination findings. A single pathologist reviewed all biopsy specimens. All men had a minimum of 12 biopsy cores taken at the time of diagnosis.
RESULTS: A 3-year followup interval biopsy eight (25.8%) men had prostate cancer, 11 (35.5%) had high grade prostatic intraepithelial neoplasia only and 12 (38.7%) had no disease. Mean serum PSA at diagnosis and before the followup biopsy was 6.88 and 9.69 ng./dl., respectively (p = 0.008). Of the men 48% had less than a 1.0 unit increase in serum PSA. Upon univariate regression analysis change in serum PSA was not associated with the detection of prostate cancer (p >0.10). All 4 patients who subsequently underwent radical prostatectomy had organ confined disease.
CONCLUSIONS: In a high proportion of men with high grade prostatic intraepithelial neoplasia prostate cancer will develop in a 3-year interval. Our findings support the concept that high grade prostatic intraepithelial neoplasia is a precursor to prostate cancer and that repeat biopsy at a delayed interval is recommended regardless of changes in PSA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352407     DOI: 10.1097/01.ju.0000028091.36436.21

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

1.  Optimizing prostate biopsy strategies for the diagnosis of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

2.  20-year-old male with recurrent right flank pain.

Authors:  Ojas Shah; Brian R Matlaga; Dean G Assimos
Journal:  Rev Urol       Date:  2003

3.  Discussion of Last Issue's Case Scenario.

Authors: 
Journal:  Rev Urol       Date:  2005

4.  Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary?

Authors:  Arnold I Chin; Dhiren S Dave; Jacob Rajfer
Journal:  Rev Urol       Date:  2007

Review 5.  Differing levels of testosterone and the prostate: a physiological interplay.

Authors:  S Larry Goldenberg; Anthony Koupparis; Michael E Robinson
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

6.  Risk perception and psychological morbidity in men at elevated risk for prostate cancer.

Authors:  A G Matthew; T Davidson; S Ochs; K L Currie; A Petrella; A Finelli
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

Review 7.  [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Authors:  L Rinnab; K Gust; R E Hautmann; R Küfer
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

Review 8.  Prostate cancer: diagnosis and staging.

Authors:  Nigel Borley; Mark R Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

Review 9.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

10.  Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience.

Authors:  Paras B Singh; Caroline M Nicholson; Narasimhan Ragavan; Rosemary A Blades; Francis L Martin; Shyam S Matanhelia
Journal:  BMC Urol       Date:  2009-05-27       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.